{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:54:02Z","timestamp":1774562042455,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the emergence of new SARS-Cov2 variants, critical questions have arisen about: (1) the effectiveness of the available COVID-19 vaccines developed to protect against the original Wuhan (wild type) variant and (2) the magnitude and clinical consequences of post-vaccination infections in the context of the Delta variant of SARS-Cov2. While some \u201creal world\u201d experiences with various vaccines have been reported, to our knowledge, few have examined comparative outcomes of various vaccines in one country as new SARS-CoV-2 variants have emerged. Here we present an analysis of COVID-19 related outcomes from a national database in Bahrain, a country with a total population of 1.51 million, where four vaccines were deployed (total vaccinated\u2009=\u20091,003,960 adults): AstraZeneca (AZ\/Covishield), Pfizer\/BioNtech, Sinopharm and Sputnik V. We compare the four vaccines, based on the following post-vaccination outcomes: SARS-CoV-2 infections, hospitalisations, ICU admissions and deaths, compared to unvaccinated individuals. We conclude that the four vaccines used in Bahrain were effective in significantly reducing all four COVID-19 related outcomes compared to unvaccinated individuals, prior to, and during the period when the Delta variant predominated in the country. However, compared to the three other vaccines, individuals vaccinated with Sinopharm vaccine had a higher risk of post-vaccination infections, hospitalisations and ICU admissions (e.g., 6.94%, 2.24%, 1.99% and 1.52% of COVID-19 cases of Sinopharm, Sputnik V, Pfizer and Covishield recipients, respectively, required hospitalisation versus 13.66% of COVID-19 cases among unvaccinated individuals); however, given the confounding factors, this needs to be confirmed by further studies. We find no evidence of biased selection for any vaccine, but note waning protection of the Pfizer\/BioNtech vaccine during the January to June 2021 period in the age\u2009&gt;\u200960 y cohort; however, this cannot be distinguished from the overall fall in hospitalisations overall. Our findings support the value of vaccination in preventing COVID-19 related outcomes, provide real world estimates on the outcomes and frequencies of post-vaccination infections for the four vaccines, which may inform vaccine selection in the context of the Delta variant across the globe.<\/jats:p>","DOI":"10.1038\/s41598-022-12543-4","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T15:06:18Z","timestamp":1654182378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain"],"prefix":"10.1038","volume":"12","author":[{"given":"Manaf","family":"AlQahtani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujoy","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulla","family":"Alawadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamad","family":"Al Mahmeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaleela","family":"Al Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Justman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafaa M.","family":"El-Sadr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Hidary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"12543_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA 326, 35\u201345 (2021).","journal-title":"JAMA"},{"key":"12543_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397, 671\u2013681 (2021).","journal-title":"Lancet"},{"key":"12543_CR4","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"12543_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. N. Engl. J. Med. 385, 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0836","volume":"145","author":"TA Adebanjo","year":"2020","unstructured":"Adebanjo, T. A. et al. Pneumococcal conjugate vaccine breakthrough infections: 2001\u20132016. Pediatrics 145, e20190836 (2020).","journal-title":"Pediatrics"},{"key":"12543_CR8","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1016\/j.vaccine.2021.05.011","volume":"39","author":"JM Ferdinands","year":"2021","unstructured":"Ferdinands, J. M. et al. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine 39, 3678\u20133695 (2021).","journal-title":"Vaccine"},{"key":"12543_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","volume":"22","author":"M Antonelli","year":"2022","unstructured":"Antonelli, M. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 22, 43\u201355 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"12543_CR10","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.15585\/mmwr.mm7046a4","volume":"70","author":"AL Naleway","year":"2021","unstructured":"Naleway, A. L. et al. Incidence of SARS-CoV-2 infection, emergency department visits, and hospitalizations because of COVID-19 among persons aged \u226512 years, by COVID-19 vaccination status\u2014Oregon and Washington, July 4\u2013September 25, 2021. MMWR Morb. Mortal Wkly. Rep. 70, 1608\u20131612 (2021).","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"12543_CR11","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMc2101927","volume":"384","author":"J Keehner","year":"2021","unstructured":"Keehner, J. et al. SARS-CoV-2 infection after vaccination in health care workers in California. N. Engl. J. Med. 384, 1774\u20131775 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474\u20131484 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-021-01413-7","volume":"27","author":"T Kustin","year":"2021","unstructured":"Kustin, T. et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat. Med. 27, 1379\u20131384 (2021).","journal-title":"Nat. Med."},{"key":"12543_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2107715","volume":"385","author":"A Jara","year":"2021","unstructured":"Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N. Engl. J. Med. 385, 875\u2013884 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114114","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. N. Engl. J. Med. 385, e85 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1943","volume":"374","author":"H Chung","year":"2021","unstructured":"Chung, H. et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: Test negative design study. BMJ 374, n1943 (2021).","journal-title":"BMJ"},{"key":"12543_CR18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","volume":"397","author":"VJ Hall","year":"2021","unstructured":"Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study. Lancet 397, 1725\u20131735 (2021).","journal-title":"Lancet"},{"key":"12543_CR19","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","volume":"385","author":"T Pilishvili","year":"2021","unstructured":"Pilishvili, T. et al. Effectiveness of mRNA Covid-19 vaccine among US health care personnel. N. Engl. J. Med. 385, e90 (2021).","journal-title":"N. Engl. J. Med."},{"key":"12543_CR20","unstructured":"https:\/\/www.ecdc.europa.eu\/en\/news-events\/weekly-epidemiological-update-omicron-variant-concern-voc-week-1-data-7-january-2022"},{"key":"12543_CR21","first-page":"2000045","volume":"25","author":"VM Corman","year":"2020","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020).","journal-title":"Euro Surveill."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12543-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12543-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:44:37Z","timestamp":1669347877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-12543-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["12543"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-12543-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9236"}}